Company intelligence
Nkarta, Inc.
A New Way Forward for Autoimmune Disease
About Nkarta, Inc.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.
Verified activity
Signals from Nkarta, Inc.
4 published signals
Presence & Recognition
Nkarta, Inc. announced that it will be presenting three abstracts including two oral presentations at American College of Rheumatology Convergence 2026 in Orlando this November.
Reported by Nkarta, Inc.
Products & Services
Nkarta, Inc. launched Facebook and Instagram channels dedicated to sharing the experiences and perspectives of people living with autoimmune diseases.
Reported by Nkarta, Inc.
Presence & Recognition
Nkarta, Inc. will be presenting 3 abstracts at American College of Rheumatology Convergence 2026, including 2 oral presentations.
Reported by Shawn Rose MD, PhD
Presence & Recognition
Nkarta, Inc. employee Anthony Amatucci, Head of Medical Affairs, discussed the potential of NK cell therapy, progress made to date, and anticipated milestones ahead with Nkarta’s Head of Medical Affairs.
Reported by Nkarta, Inc.